• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Krystal Biotech Inc.

    2/5/25 7:51:21 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KRYS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    KRYSTAL BIOTECH INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    501147102

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    501147102


    1Names of Reporting Persons

    STATE STREET CORPORATION
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,183,811.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,278,975.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,278,975.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.4 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    KRYSTAL BIOTECH INC
    (b)Address of issuer's principal executive offices:

    2100 WHARTON STREET SUITE 701 , PITTSBURGH, PENNSYLVANIA, 15203
    Item 2. 
    (a)Name of person filing:

    STATE STREET CORPORATION;
    (b)Address or principal business office or, if none, residence:

    ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES
    (c)Citizenship:

    MA
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    501147102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1278975.00
    (b)Percent of class:

    4.4  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    1,183,811

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    1,278,975

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    NOT APPLICABLE
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    SSGA FUNDS MANAGEMENT, INC. (IA);STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA);STATE STREET GLOBAL ADVISORS LIMITED (IA);STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA);STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED (IA);STATE STREET GLOBAL ADVISORS, LTD. (IA);
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    NOT APPLICABLE
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    NOT APPLICABLE

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    STATE STREET CORPORATION
     
    Signature:ELIZABETH SCHAEFER
    Name/Title:SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
    Date:01/31/2025
    Get the next $KRYS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KRYS

    DatePrice TargetRatingAnalyst
    1/6/2026$309.00Neutral → Buy
    Citigroup
    3/5/2025$245.00Buy
    Jefferies
    8/6/2024$195.00 → $204.00Buy → Neutral
    Citigroup
    11/20/2023$160.00Buy
    Goldman
    10/24/2023$100.00Overweight
    Cantor Fitzgerald
    10/12/2023$160.00Buy
    Citigroup
    9/7/2023$154.00Buy
    Berenberg
    4/18/2023$102.00Buy
    Stifel
    More analyst ratings

    $KRYS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

    PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Tuesday, February 17, 2026, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53598. For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company's websi

    2/10/26 8:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

    PITTSBURGH, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that the United States Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, the Company's redosable immunotherapy designed to drive sustained, localized expression of interleukin-2 and interleukin-12 in the tumor microenvironment, for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). "The FDA's decision to grant RMAT designation to KB707 reflects both the urgent unmet need for new NSCLC therapies as well as the promising early clinical evidence of efficacy we have observed with inhaled KB707 in

    2/9/26 8:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

    Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced selected preliminary unaudited 2025 financial results, including fourth quarter and full year 2025 VYJUVEK® net product revenue, and outlined the Company's strategic vision to drive the next stage of growth of its rare disease business. These topics will be discussed during the Company's presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco tomorrow, Monday, January 1

    1/11/26 1:00:00 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 19, 2023 - FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa

    For Immediate Release: May 19, 2023 Today, the U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.  “Vyjuvek is the first FDA-approved gene therapy treatment for DEB, a

    5/19/23 1:48:20 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Krystal Biotech upgraded by Citigroup with a new price target

    Citigroup upgraded Krystal Biotech from Neutral to Buy and set a new price target of $309.00

    1/6/26 8:26:47 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies initiated coverage on Krystal Biotech with a new price target

    Jefferies initiated coverage of Krystal Biotech with a rating of Buy and set a new price target of $245.00

    3/5/25 7:35:58 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Krystal Biotech downgraded by Citigroup with a new price target

    Citigroup downgraded Krystal Biotech from Buy to Neutral and set a new price target of $204.00 from $195.00 previously

    8/6/24 8:53:09 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    SEC Filings

    View All

    Krystal Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Krystal Biotech, Inc. (0001711279) (Filer)

    1/12/26 7:50:51 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Krystal Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Krystal Biotech, Inc. (0001711279) (Filer)

    1/8/26 4:35:06 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Krystal Biotech Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Krystal Biotech, Inc. (0001711279) (Filer)

    12/23/25 4:51:08 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Romano Kathryn exercised 12,500 shares at a strike of $63.55, sold $3,401,705 worth of shares (12,500 units at $272.14) and gifted 750 shares, decreasing direct ownership by 4% to 18,568 units (SEC Form 4)

    4 - Krystal Biotech, Inc. (0001711279) (Issuer)

    2/11/26 7:08:54 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President, R&D Krishnan Suma sold $11,007,333 worth of shares (50,000 units at $220.15) and gifted 5,000 shares, decreasing direct ownership by 2% to 1,413,711 units (SEC Form 4)

    4 - Krystal Biotech, Inc. (0001711279) (Issuer)

    12/5/25 6:56:19 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Krishnan Krish S sold $11,007,447 worth of shares (50,000 units at $220.15) and gifted 5,000 shares, decreasing direct ownership by 2% to 1,478,056 units (SEC Form 4)

    4 - Krystal Biotech, Inc. (0001711279) (Issuer)

    12/5/25 6:53:44 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    Leadership Updates

    Live Leadership Updates

    View All

    Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

    PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an extensive track record of building innovative companies as well as launching and commercializing leading brands, including BOTOX®, one of the most widely recognized global brands. Mr. Forth

    4/7/25 4:30:00 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

    PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Nishant Saxena as Chief Financial Officer (CFO), effective January 15, 2025. Mr. Saxena has over 20 years of experience in finance, strategy, capital markets, mergers and acquisitions, and corporate development. Most recently, he was a Managing Director in Evercore's healthcare group, where he advised on transactions totaling over $500 billion in aggregate value. "It is my

    1/14/25 8:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S

    6/7/24 6:09:00 PM ET
    $ADTN
    $ALTR
    $ATNI
    Telecommunications Equipment
    Utilities
    Computer Software: Prepackaged Software
    Technology

    $KRYS
    Financials

    Live finance-specific insights

    View All

    Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

    PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Tuesday, February 17, 2026, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53598. For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company's websi

    2/10/26 8:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis

    Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespective of modulator-status; percentage of conducting airway cells transduced in each patient ranged from 29.4% to 42.1% Registrational repeat dosing CORAL-3 study design submitted to FDA in late December; anticipating enrollment in study to start in 1H 2026 following alignment with the FDA Investor call to be held January 8 at 4:30 pm ET to discuss data update and timelines for KB407 repeat dosing study start PITTSBURGH, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company"

    1/8/26 4:01:00 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis

    PITTSBURGH, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that it will host an investor conference call and webcast tomorrow, Thursday, January 8, 2026, at 4:30 pm ET, to disclose an interim clinical update from CORAL-1, the Company's multi-center, dose escalation Phase 1 study evaluating KB407 in patients with cystic fibrosis. The interim clinical update will focus on results from patients in the highest dose cohort of CORAL-1 and include molecular assessments of KB407 transduction and wild-type cystic fibrosis transmembrane conductance regulator (CFTR) protein expression following inhaled administration of KB407. Investors and the

    1/7/26 4:05:00 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

    SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)

    11/14/24 9:00:58 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

    SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)

    11/12/24 10:32:12 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Krystal Biotech Inc.

    SC 13G - Krystal Biotech, Inc. (0001711279) (Subject)

    10/16/24 12:28:49 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care